Currently the best alternative for treatment of depression after conventional medications or therapy have failed is electroconvulsive therapy (ECT).

In this treatment, a person is anesthetized and a finely controlled electrical current is applied to the brain. While the technique is often beneficial, many choose not to take advantage of it because of the treatment’s side effects and public misperception of the procedure.

If the results of a campus-wide collaboration of University of Utah researchers are borne out by larger studies and trials, patients with difficult-to-treat depression might one day have an alternative that is as effective as ECT but without the side effects – the surgical anesthetic drug isoflurane.

“We need to expand our research into a larger, multicenter trial, but if the results of our pilot study pan out, it would change the face of treating depression,” said Howard R. Weeks, M.D., the first author on a study published in the journal PLOS One online.

Also known as shock therapy, ECT is effective in 55 percent to 90 percent of depression cases, with significant reductions in symptoms typically occurring within two to four weeks. When medications work, they can take six to eight weeks to become effective.

But ECT is associated with side effects including amnesia, concentration and attention problems, and other cognitive issues.

Many people also mistakenly believe ECT is painful and causes brain damage, which has given the treatment a social stigma that makes millions of patients reluctant to have the therapy.

Researchers believe isoflurane offers a potential alternative to ECT that could help many people.

In a pilot study with 20 patients who received ECT treatments compared with eight patients who received the isoflurane treatments, the researchers found that both therapies provided significant reduction in symptoms of depression.

Immediately following the treatments, ECT patients showed declines in areas of memory, verbal fluency, and processing speed. Most of these ECT-related deficits did resolve by four weeks.

However, autobiographical memory, or recall of personal life events, remained below pretreatment levels for ECT patients four weeks after the treatment.

In contrast, the patients treated with isoflurane showed no real impairment but instead had greater improvements in cognitive testing than ECT patients both immediately and four weeks after the treatments.

Recently, another anesthetic, ketamine, has drawn interest as a potential treatment for depression. But studies so far have not shown long-lasting effects from ketamine. In contrast, isoflurane showed continued antidepressant effects four weeks after the treatments.

In the mid-1980s, researchers in Europe studied isoflurane as a potential depression therapy. Later studies by other scientists, however, failed to confirm the results of the original work and isoflurane research fell out of favor.

But these later studies didn’t adhere to the first study’s protocol regarding type of anesthetic, dosing size and number of treatments, according to Weeks, and he believes that’s why isoflurane’s antidepressant effects weren’t confirmed in subsequent trials.

For their research, Weeks and his colleagues followed the original study’s protocol. “Our data reconfirm that isoflurane had an antidepressant effect approaching ECT with less adverse neurocognitive effects, and reinforce the need for a larger clinical trial,” the researchers wrote.

Still, researchers are uncertain as to what produces the relief of depression symptoms from ECT or isoflurane.

Weeks believes further study might identify a molecular pathway that both therapies target and is responsible for the improvement in depression.

One common effect of both ECT and isoflurane treatments is a brief state of low electrical activity in which the brain becomes unusually quiet.

ECT induces a seizure to reach that state, but isoflurane does not. After inhaling the anesthesia, patients are “under” for about 45 minutes, with 15 minutes of that time being a deep state of unconsciousness, according to Weeks.

This period of electrical rest for the brain may be a potential explanation for why ECT and isoflurane improve depression.

If isoflurane proves to be a viable alternative to ECT, a device invented by three University of Utah anesthesiology faculty members can make the anesthetic an even more attractive therapy.

The Aneclear™ device uses hyperventilation and allows patients to rebreathe their own carbon dioxide (C02). Hyperventilation removes anesthesia from the lungs and C02 encourages blood flow to the brain, which encourages quicker removal of anesthetic.

The Aneclear™ also minimizes or even eliminates vomiting, nausea and extreme fatigue that some patients experience from anesthesia.

“With the Aneclear™, we can wake people up from the anesthesia much quicker,” Weeks says. “This makes the treatment a potentially viable clinical treatment by reducing the time required in an operating room.”

Weeks and his co-researchers now are looking for grants to fund a larger study that will include several U.S. centers.

Source: University of Utah Health Sciences

Woman being anesthetized photo by shutterstock.

For Drug-Resistant Depression, A Choice Other Than ECT